Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model

Cancer Nanotechnology

Hua-Ching Lin¹  Anya Maan-Yuh Lin²  Chen-Shen Wang³  Chih-Hsien Chang³  Shu-Ting Hong³  Yu-Li Lo⁴ 

[1]Division of Colorectal Surgery, Surgical Department, Chen-Hsin General Hospital, Taipei, Taiwan

[2]Department of Healthcare Information and Management, Ming Chuan University, Taoyuan, Taiwan

[3]Faculty of Pharmacy, National Yang Ming Chiao Tung University, 112, Taipei, Taiwan

[4]Department of Medical Research, Taipei Veterans General Hospital, 112, Taipei, Taiwan

[5]Institute of Pharmacology, National Yang Ming Chiao Tung University, 112, Taipei, Taiwan

[6]Institute of Pharmacology, National Yang Ming Chiao Tung University, 112, Taipei, Taiwan

[7]Faculty of Pharmacy, National Yang Ming Chiao Tung University, 112, Taipei, Taiwan

[8]Center for Advanced Pharmaceutics and Drug Delivery Research, National Yang Ming Chiao Tung University, 112, Taipei, Taiwan

关键词: Afatinib;    Blood–brain barrier;    Lipid polymeric nanoparticle;    Tight junction-modulating peptide;    Lung cancer;    Brain metastasis;   

DOI  :  10.1186/s12645-021-00084-w

来源: Springer

【 摘 要 】

BackgroundBrain metastases from non-small cell lung cancer (NSCLC) remain one of the most challenging malignancies. Afatinib (Afa) is an orally administered irreversible ErbB family blocker approved for epidermal growth factor receptor (EGFR)-mutated NSCLC. However, the incidence of brain metastases in patients with NSCLC and EGFR mutation is high. One of the major obstacles in the treatment of brain metastases is to transport drugs across the blood–brain barrier (BBB). A lipid polymeric nanoparticle (LPN) modified with a tight junction-modulating peptide is a potential formulation to deliver therapeutics across the BBB. FD7 and CCD are short peptides that perturb the tight junctions (TJs) of the BBB. In this study, the use of LPN modified with FD7 or CCD as a delivery platform was explored to enhance Afa delivery across the BBB model of mouse brain-derived endothelial bEnd.3 cells.ResultsOur findings revealed that Afa/LPN-FD7 and Afa/LPN-CCD exhibited a homogeneous shape, a uniform nano-scaled particle size, and a sustained-release profile. FD7, CCD, Afa/LPN-FD7, and Afa/LPN-CCD did not cause a significant cytotoxic effect on bEnd.3 cells. Afa/LPN-FD7 and Afa/LPN-CCD across the bEnd.3 cells enhanced the cytotoxicity of Afa on human lung adenocarcinoma PC9 cells. FD7 and CCD-modulated TJ proteins, such as claudin 5 and ZO-1, reduced transendothelial electrical resistance, and increased the permeability of paracellular markers across the bEnd.3 cells. Afa/LPN-FD7 and Afa/LPN-CCD were also partially transported through clathrin- and caveolae-mediated transcytosis, revealing the effective activation of paracellular and transcellular pathways to facilitate Afa delivery across the BBB and cytotoxicity of Afa on PC9 cells.ConclusionTJ-modulating peptide-modified LPN could be a prospective platform for the delivery of chemotherapeutics across the BBB to the brain for the potential treatment of the BM of NSCLC.

【 授权许可】

CC BY